AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials

Author's Avatar
Aug 17, 2020
Article's Main Image

Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollment